Relapse after allogeneic stem cell transplantation
Authors:
- 1 August 2010
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 3 (4) , 429-441
Abstract
Since allogeneic stem cell transplantation (SCT) represents an intensive curative treatment for high-risk malignancies, its failure to prevent relapse leaves few options for successful salvage trea...Keywords
This publication has 107 references indexed in Scilit:
- NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia ReactionTransplantation and Cellular Therapy, 2010
- Relapse after Allogeneic Hematopoietic Cell TherapyTransplantation and Cellular Therapy, 2010
- Dichotomous Role of Interferon-γ in Allogeneic Bone Marrow TransplantTransplantation and Cellular Therapy, 2009
- Safety and immunologic effects of IL-15 administration in nonhuman primatesBlood, 2009
- Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomibBlood, 2009
- Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemiaBlood, 2009
- Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative ConditioningTransplantation and Cellular Therapy, 2008
- Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem Cell TransplantationTransplantation and Cellular Therapy, 2007
- Translational Mini-Review Series on Vaccines:
Peptide vaccines for myeloid leukaemiasClinical and Experimental Immunology, 2007
- High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCTBlood, 2006